Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial
Published at: jco.ascopubs.org
-
Can Xeloda Triumph 5-FU? Yes! Will It? That's Another Story!
September 21, 2007
Can Xeloda replace 5-FU, it sure can! Though, I'm just as sure that it won't and data (in terms of efficacy) is not the reason for Roche's woes! The Spanish data has just added another brick in the wall of data supporting Roche's battle to get Xeloda to overtake 5-FU, though it’s already a pretty well developed wall! If anything the lukewarm reception that awaits the data further suggests that Roche has missed the boat on Xeloda!
-
Donald FlemingDirector of the Cancer Care Center DAVIS HEALTH SYSTEM, INC.
September 20, 2007
Xeloda has proven equal to infusional 5FU in recent colorectal cancer trial Xeloda is an oral agent versus iv 5FU and is therefore prefered therapy Xeloda has a diffrenet toxicity profile than infusional 5FU
-
Capecitabine-replaces infusional 5FU?
September 19, 2007
Capecitabine can replace 5FU in the FOLFOX program for CRC (And by inference in all infusional programs for 5FU)
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.